BMS Fuels its Fibrotic Disease Pipeline with US$1.25 B Deal for Promedior
By Heather Cartwright & Sayani Datta
Pharma Deals Review: Vol 2015 Issue 10 (Table of Contents)
Published: 13 Oct-2015
DOI: 10.3833/pdr.v2015.i10.2126 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Continuing its preference for option-based deal structures, Bristol-Myers Squibb (BMS) has secured the right to acquire privately held Promedior in a deal potentially worth up to US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS